A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

NCT02222922 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: PF-06647020 Q3W
DRUG: fluconazole
DRUG: PF-06647020 Q2W
DRUG: PF-06647020 combined with Avelumab

Sponsor

Pfizer